Renascience Inc. Logo

Renascience Inc.

A drug discovery venture developing medicines for diseases of tissue aging.

4889 | T

Overview

Corporate Details

ISIN(s):
JP3981100005
LEI:
Country:
Japan
Address:
仙台市青葉区星陵町2−1

Description

Renascience Inc. is a drug discovery venture originating from Tohoku University. The company focuses on the research and development of various medical modalities, including pharmaceuticals, medical devices, and artificial intelligence (AI) applications. A primary area of its R&D is the study of cellular senescence at the molecular level to develop novel medicines for diseases associated with tissue aging. While initially founded with a focus on kidney disease, Renascience collaborates with academic institutions and corporate partners to advance its diverse R&D pipelines through clinical trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-19 07:34
発行登録追補書類(株券、社債券等)
Japanese ZIP 266.1 KB
2025-12-19 07:32
発行登録追補書類(株券、社債券等)
Japanese ZIP 189.5 KB
2025-12-09 07:34
発行登録追補書類(株券、社債券等)
Japanese ZIP 255.4 KB
2025-12-09 07:33
発行登録追補書類(株券、社債券等)
Japanese ZIP 185.6 KB
2025-11-28 07:32
発行登録書(株券、社債券等)
Japanese ZIP 353.6 KB
2025-11-28 07:31
発行登録書(株券、社債券等)
Japanese ZIP 188.6 KB
2025-11-12 07:39
確認書
Japanese ZIP 8.7 KB
2025-11-12 07:37
半期報告書-第27期(2025/04/01-2026/03/31)
Japanese ZIP 434.5 KB
2025-09-03 08:37
確認書
Japanese ZIP 8.7 KB
2025-09-03 08:30
訂正有価証券報告書-第26期(2024/04/01-2025/03/31)
Japanese ZIP 1.7 MB
2025-06-27 08:35
臨時報告書
Japanese ZIP 23.6 KB
2025-06-24 08:36
内部統制報告書-第26期(2024/04/01-2025/03/31)
Japanese ZIP 23.2 KB
2025-06-24 08:35
確認書
Japanese ZIP 8.7 KB
2025-06-24 08:33
有価証券報告書-第26期(2024/04/01-2025/03/31)
Japanese ZIP 3.5 MB
2024-11-14 07:37
確認書
Japanese ZIP 8.7 KB

Automate Your Workflow. Get a real-time feed of all Renascience Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Renascience Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Renascience Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.